Table 1 (abstract P168). See text for description
From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)
| Â | Non-Systemic JIA Starting TNF N=793 | Systemic JIA Start IL-1/6 N=85 |
|---|---|---|
Registered Biologic therapy | ||
 Etanercept | 544 (69%) | - |
 Infliximab | 28 (4%) | - |
 Anakinra | - | 28 (33%) |
 Adalimumab | 220 (28%) | - |
 Tocilizumab | - | 57 (67%) |
 Golimumab | 1 (<1%) | - |
Concomitant MTX | 450 (57%) | 58 (68%) |
Female | 527 (66%) | 49 (58%) |
Age, years | ||
 Median (IQR) | 12 (8, 14) | 7 (3, 12) |
 Min to Max | 1 to 20 | 1 to 17 |
Disease Duration, years | N=782 | N=85 |
 Median (IQR) | 1 (1, 4) | 1 (0, 1) |
 Min to Max | 0 to 18 | 0 to 9 |
Remission (% of whole cohort) | 131 (17%) | 25 (29%) |
Time to Remission, years | 2.2 (2.0, 2.9) | 2.2 (1.5, 3.2) |
Time to end of follow-up, if >0 | 1.5 (0.8, 2.5) N=123 | 1.4 (0.8, 2.5) N=24 |
Re-started biologic therapy | 58 (44%) | 5 (20%) |
 Time to re-start, years | 0.4 (0.2, 0.7) | 0.4 (0.1, 0.4) |
 Re-started same biologic | 49 (84%) | 4 (80%) |